Abstract #2919

Amide proton transfer (APT) MRI is a predictor of survival and progression in high-grade glioma patients

Daniel Paech¹, Constantin Dreher¹, Sebastian Regnery¹, Jan-Eric Meissner², Steffen Goerke², Johannes Windschuh², Katerina Deike-Hofmann¹, Sebastian Bickelhaupt¹, Alexander Radbruch³, Moritz Zaiss⁴, Andreas Unterberg⁵, Wolfgang Wick⁶, Martin Bendszus⁷, Peter Bachert², Mark Edward Ladd², and Heinz-Peter Schlemmer¹

¹Radiology, German Cancer Research Center, Heidelberg, Germany, ²Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany, ³Radiology, University Hospital Essen, Essen, Germany, ⁴Max-Planck-Institut Tuebingen, Tuebingen, Germany, ⁵Neurosurgery, University of Heidelberg, Heidelberg, Germany, ⁶Neurology, University of Heidelberg, Heidelberg, Germany, ⁷Neuroradiology, University of Heidelberg, Heidelberg, Germany

In this work we show that relaxation-compensated amide proton transfer (APT) imaging at 7.0 T is associated with overall survival and progression-free survival in newly-diagnosed, previously untreated glioma patients. The current study showed that glioma patients with increased APT values were more likely to progress sooner and live shorter, respectively. This effect may be caused by strong alterations of amino acid concentrations and global upregulation of protein expression in more aggressive brain tumors. Therefore, APT CEST imaging may help to enhance the prognostic value of non-invasive MRI tools at the time of initial diagnosis and during follow-up.

This abstract and the presentation materials are available to members only; a login is required.

Join Here